ES2178510A1 - Composiciones farmaceuticas de micofenolato revestidas entericamente. - Google Patents

Composiciones farmaceuticas de micofenolato revestidas entericamente.

Info

Publication number
ES2178510A1
ES2178510A1 ES009850018A ES9850018A ES2178510A1 ES 2178510 A1 ES2178510 A1 ES 2178510A1 ES 009850018 A ES009850018 A ES 009850018A ES 9850018 A ES9850018 A ES 9850018A ES 2178510 A1 ES2178510 A1 ES 2178510A1
Authority
ES
Spain
Prior art keywords
mycophenolate
enteric
pharmaceutical compositions
coated pharmaceutical
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009850018A
Other languages
English (en)
Other versions
ES2178510B1 (es
Inventor
Barbara Haeberlin
Ching Pong Mak
Armin Meinzer
Jacky Vonderscher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2178510(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9607564.3A external-priority patent/GB9607564D0/en
Priority claimed from GBGB9622028.0A external-priority patent/GB9622028D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of ES2178510A1 publication Critical patent/ES2178510A1/es
Application granted granted Critical
Publication of ES2178510B1 publication Critical patent/ES2178510B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA SAL DE MICOFENOLATO, ESTANDO ADAPTADA LA COMPOSICION PARA LIBERAR EL MICOFENOLATO EN LA PARTE SUPERIOR DEL TRACTO INTESTINAL.
ES009850018A 1996-04-12 1997-04-10 Composiciones farmaceuticas de micofenolato revestidas entericamente. Expired - Fee Related ES2178510B1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9607564 1996-04-12
GBGB9607564.3A GB9607564D0 (en) 1996-04-12 1996-04-12 Organic compounds
GB9622028 1996-10-24
GBGB9622028.0A GB9622028D0 (en) 1996-10-24 1996-10-24 Organic compounds

Publications (2)

Publication Number Publication Date
ES2178510A1 true ES2178510A1 (es) 2002-12-16
ES2178510B1 ES2178510B1 (es) 2004-08-16

Family

ID=26309105

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009850018A Expired - Fee Related ES2178510B1 (es) 1996-04-12 1997-04-10 Composiciones farmaceuticas de micofenolato revestidas entericamente.
ES97919330T Expired - Lifetime ES2216141T3 (es) 1996-04-12 1997-04-10 Composiciones farmaceuticas de micofenolato con recubrimiento enterico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES97919330T Expired - Lifetime ES2216141T3 (es) 1996-04-12 1997-04-10 Composiciones farmaceuticas de micofenolato con recubrimiento enterico.

Country Status (34)

Country Link
US (3) US6025391A (es)
EP (2) EP1221316A1 (es)
JP (2) JP3779732B2 (es)
CN (1) CN1104238C (es)
AR (2) AR006583A1 (es)
AT (2) AT408415B (es)
AU (1) AU725388B2 (es)
BE (1) BE1010963A3 (es)
BR (1) BR9708624A (es)
CO (1) CO4900024A1 (es)
CY (1) CY2243B1 (es)
CZ (1) CZ291811B6 (es)
DE (4) DE69727559T2 (es)
DK (1) DK0892640T3 (es)
ES (2) ES2178510B1 (es)
FR (1) FR2747920B1 (es)
GB (1) GB2326339B (es)
GR (1) GR1002893B (es)
HK (1) HK1051484A1 (es)
HU (1) HU224919B1 (es)
ID (1) ID18663A (es)
IE (1) IE970267A1 (es)
IL (1) IL126431A (es)
IT (1) IT1297045B1 (es)
LU (1) LU91094I2 (es)
MY (1) MY119049A (es)
NL (1) NL300157I2 (es)
NO (2) NO322891B1 (es)
NZ (1) NZ332117A (es)
PT (1) PT892640E (es)
RU (2) RU2615397C2 (es)
TR (1) TR199802056T2 (es)
TW (1) TW457098B (es)
WO (1) WO1997038689A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067773A2 (en) * 1999-05-10 2000-11-16 Novartis Ag Combinations of immunosupressive agents for the treatment or prevention of graft rejections
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
EP1435910B9 (en) * 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
RU2277090C9 (ru) * 2002-08-29 2006-09-10 Байокон Лимитид Способ получения натриевой соли микофеноловой кислоты, являющейся иммунодепрессантным средством
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0314553D0 (en) * 2003-06-21 2003-07-30 Weatherford Lamb Electric submersible pumps
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
CA2560613C (en) * 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
WO2005105768A2 (en) * 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005658A (es) 2004-04-27 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
TWI322147B (en) 2004-07-20 2010-03-21 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086498A2 (en) 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
PL2278002T3 (pl) * 2005-07-29 2017-12-29 Abbott Laboratories Gmbh Pankreatyna o zmniejszonej zawartości wirusowej
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
CN1985994B (zh) * 2005-12-19 2011-01-12 康泰乐(北京)医药科技发展有限公司 改进的包含霉酚酸盐的包有肠溶衣的药物组合物
KR20080094788A (ko) * 2006-02-13 2008-10-24 노파르티스 아게 고복용량의 미코페놀산(엠피에이)
JP2007230948A (ja) * 2006-03-02 2007-09-13 Univ Meijo 腸溶性化硬カプセル
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
PL2032712T3 (pl) * 2006-06-29 2010-07-30 Ivax Pharmaceuticals Sro Regulacja wytwarzania kwaśnego metabolitu
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
US20080182998A1 (en) * 2007-01-25 2008-07-31 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
MX2008015797A (es) * 2007-04-11 2009-03-06 Teva Gyogyszergyar Zartkoeruen Metodo para reducir el nivel de impurezas en la fermentacion del acido micofenolico.
AU2008288106B2 (en) * 2007-08-13 2012-03-15 Panacea Biotec Limited Extended release compositions comprising mycophenolate sodium and processes thereof
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
JP2011527339A (ja) * 2008-07-09 2011-10-27 アスプレバ インターナショナル リミテッド 眼障害を処置するためのミコフェノール酸ナトリウムのｐＨ特異的な溶液
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
EA201270544A1 (ru) * 2009-10-13 2012-09-28 Тева Фармасьютикал Индастриз Лтд. Композиции с отсроченным высвобождением
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
MX386935B (es) 2013-03-14 2025-03-04 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
BR112016015766A2 (pt) 2014-01-06 2017-08-08 Iron Therapeutics Holdings Ag Regime de dosagem de trimaltol férrico
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
MX2019010829A (es) * 2017-03-13 2020-02-05 Okava Pharmaceuticals Inc Metodos y composiciones para suministrar agentes activos de acido micofenolico a mamiferos no humanos.
BR112022018055A2 (pt) * 2020-03-11 2022-10-18 Amorphical Ltd Carbonato de cálcio amorfo para tratamento de acidose.
CA3212370A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
CN114028334B (zh) * 2021-12-10 2023-08-29 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE704326A (es) * 1966-09-27 1968-03-26
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
WO1994026266A1 (en) * 1993-05-13 1994-11-24 Syntex (U.S.A.) Inc. High dose formulations

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1173942A (en) * 1967-06-06 1969-12-10 Bellon Labor Sa Roger New 2,3-Dihydro-1,4-Benzoxazines
GB1158387A (en) * 1967-06-13 1969-07-16 Ici Ltd Procedure for Isolation of Mycophenolic Acid
GB1261060A (en) * 1969-09-09 1972-01-19 Ici Ltd Phthalen-1-one derivatives
US3825571A (en) * 1971-07-31 1974-07-23 Chugai Pharmaceutical Co Ltd Mycophenolic acid derivatives
JPS5542995B2 (es) * 1972-02-24 1980-11-04
US3777020A (en) * 1972-08-14 1973-12-04 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US3868454A (en) * 1972-08-14 1975-02-25 Lilly Co Eli Psoriasis treatment with mycophenolic acid derivatives
US4005108A (en) * 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US4234684A (en) * 1979-12-11 1980-11-18 Eli Lilly And Company Method of preparing mycophenolic acid glucoside
IT1150194B (it) * 1982-02-23 1986-12-10 Chiesi Farma Spa Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
US4686234A (en) * 1985-11-27 1987-08-11 Syntex (U.S.A) Inc. Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4847381A (en) * 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US5135934A (en) * 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5372298A (en) * 1992-01-07 1994-12-13 The Regents Of The University Of California Transient liquid phase ceramic bonding
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
AU6826194A (en) * 1993-05-06 1994-12-12 Pharmagenesis, Inc. 16-hydroxytriptolide composition and method for immunotherapy
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
PL177323B1 (pl) * 1993-10-01 1999-10-29 Syntex Inc Kompozycja farmaceutyczna zawierająca mykofenolan mofetylu lub kwas mykofenolowy i sposób wytwarzania kompozycji farmaceutycznej zawierającej mykofenolan mofetylu lub kwas mykofenolowy
WO1995013082A1 (en) * 1993-11-08 1995-05-18 Pharmagenesis, Inc. Immunotherapy composition and method
EP0729471A1 (en) * 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE704326A (es) * 1966-09-27 1968-03-26
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
WO1994026266A1 (en) * 1993-05-13 1994-11-24 Syntex (U.S.A.) Inc. High dose formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRINYO J. et al. "Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection" Lancet, Vol. 345, 1995, paginas 1321-1325. *
MARINARI, R. et al. "Mycophenolic acid in the treatment of psoriasis" Arch. Dermatol., Volumen 113, 1977, paginas 930-932. *

Also Published As

Publication number Publication date
EP0892640B1 (en) 2004-02-11
NO984728L (no) 1998-12-02
TW457098B (en) 2001-10-01
IE970267A1 (en) 1997-10-22
JP3779732B2 (ja) 2006-05-31
US6306900B1 (en) 2001-10-23
MY119049A (en) 2005-03-31
IL126431A (en) 2005-03-20
CO4900024A1 (es) 2000-03-27
CY2243B1 (en) 2003-07-04
BR9708624A (pt) 1999-08-03
JP2006063086A (ja) 2006-03-09
NO322891B1 (no) 2006-12-18
HUP9903373A3 (en) 2001-05-28
EP1221316A1 (en) 2002-07-10
CZ291811B6 (cs) 2003-06-18
LU91094I2 (fr) 2004-10-11
DE69727559T2 (de) 2004-12-16
ATE259228T1 (de) 2004-02-15
DE69727559D1 (de) 2004-03-18
DK0892640T3 (da) 2004-05-10
NO984728D0 (no) 1998-10-09
AR059693A2 (es) 2008-04-23
NZ332117A (en) 2000-04-28
IT1297045B1 (it) 1999-08-03
DE122004000038I1 (de) 2006-01-26
HU224919B1 (en) 2006-04-28
ATA905997A (de) 2001-04-15
RU2615397C2 (ru) 2017-04-04
NL300157I2 (nl) 2004-12-01
US6025391A (en) 2000-02-15
HK1016490A1 (en) 1999-11-05
ITRM970207A1 (it) 1998-10-11
EP0892640A2 (en) 1999-01-27
FR2747920A1 (fr) 1997-10-31
NO2007004I1 (no) 2007-04-16
CN1104238C (zh) 2003-04-02
GB2326339A (en) 1998-12-23
RU2203659C2 (ru) 2003-05-10
AU725388B2 (en) 2000-10-12
ID18663A (id) 1998-04-30
HK1051484A1 (en) 2003-08-08
AT408415B (de) 2001-11-26
ES2178510B1 (es) 2004-08-16
GB2326339B (en) 2000-04-19
JP2000503665A (ja) 2000-03-28
HUP9903373A2 (hu) 2001-04-28
CN1215991A (zh) 1999-05-05
WO1997038689A3 (en) 1997-12-04
GB9821304D0 (en) 1998-11-25
DE19781690D2 (de) 1999-04-08
PT892640E (pt) 2004-06-30
NO2007004I2 (no) 2009-10-19
CZ326798A3 (cs) 1999-01-13
AU2384397A (en) 1997-11-07
FR2747920B1 (fr) 1999-12-31
IL126431A0 (en) 1999-08-17
GR1002893B (el) 1998-04-10
WO1997038689A2 (en) 1997-10-23
US6172107B1 (en) 2001-01-09
BE1010963A3 (fr) 1999-03-02
ES2216141T3 (es) 2004-10-16
AR006583A1 (es) 1999-09-08
DE122004000038I2 (de) 2006-04-27
NL300157I1 (nl) 2004-10-01
TR199802056T2 (xx) 1999-02-22

Similar Documents

Publication Publication Date Title
MY119049A (en) Enteric-coated pharmaceutical compositions of mycophenolate
HU9800985D0 (en) Retarde polymere compositions for pharmaceutical compositions
ZA967034B (en) Pharmaceutical compositions.
ZA974735B (en) Pharmaceutical compositions.
ZA965190B (en) Pharmaceutical composition.
ZA983170B (en) Pharmaceutical compositions having appetite suppressant activity.
ZA982253B (en) Therapeutic compositions.
ZA9711508B (en) Rapidly disintegrable pharmaceutical composition.
ZA975533B (en) Cyclosporin-containing pharmaceutical composition.
ZA987536B (en) Stanol comprising compositions.
ZA977104B (en) Pharmaceutical compositions.
ZA9710006B (en) Novel pharmaceutical compositions
ZA968081B (en) Pharmaceutical composition.
ZA9811276B (en) Non-whitening underarm compositions.
ZA9811337B (en) Acid resistant cement composition.
ZA983258B (en) Pharmaceutical composition for gastric residence
BG103649A (en) Method for the preparation of eprosartan
BG103650A (en) Method for the preparation of eprosartan
AP2001002369A0 (en) Pharmaceutical complex.
ZA99890B (en) Pharmaceutical compositions.
CA2250906A1 (en) Enteric-coated pharmaceutical compositions of mycophenolate
ZA971036B (en) Pharmaceutical compositions for the prevention or treatment of retrovirus infections.
ZA9711432B (en) Compositions for the preparation of leather.
ZA982367B (en) Pharmaceutical compositions.
GB2318056B (en) Composition for enhanced uptake of polar drugs from the colon

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20021216

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2178510B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20170726